New paradigm in asthma management: switching between biologics!

Clicks: 212
ID: 41471
2019
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Star

Ranked #12 of 14 articles by views in allergy

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
The nominalist definition acknowledges asthma as an abnormality of the airways, typically comprising of variable airflow limitation over short periods of time, hyperresponsiveness and airway inflammation (1). The severity of asthma has primarily been assessed by the level of treatment required to control symptoms and exacerbations, with corticosteroids (inhaled and/or oral) as the mainstay treatment for suppressing the overall inflammatory component (2). This article is protected by copyright. All rights reserved.
Reference Key
mukherjee2019newallergy Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Mukherjee, Manali;Bakakos, Petros;Loukides, Stelios;
Journal allergy
Year 2019
DOI
10.1111/all.14038
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.